IL307990A - Antimicrobial and anticancer agents - Google Patents
Antimicrobial and anticancer agentsInfo
- Publication number
- IL307990A IL307990A IL307990A IL30799023A IL307990A IL 307990 A IL307990 A IL 307990A IL 307990 A IL307990 A IL 307990A IL 30799023 A IL30799023 A IL 30799023A IL 307990 A IL307990 A IL 307990A
- Authority
- IL
- Israel
- Prior art keywords
- subject
- cancer
- compound
- pharmaceutical composition
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/06—Six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181492P | 2021-04-29 | 2021-04-29 | |
| PCT/IB2022/053973 WO2022229907A1 (en) | 2021-04-29 | 2022-04-28 | Antimicrobial and anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307990A true IL307990A (en) | 2023-12-01 |
Family
ID=81598080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307990A IL307990A (en) | 2021-04-29 | 2022-04-28 | Antimicrobial and anticancer agents |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12612375B2 (https=) |
| EP (1) | EP4330238A1 (https=) |
| JP (1) | JP2024515215A (https=) |
| KR (1) | KR20240004303A (https=) |
| CN (1) | CN117295720A (https=) |
| AU (1) | AU2022267897A1 (https=) |
| CA (1) | CA3216783A1 (https=) |
| IL (1) | IL307990A (https=) |
| WO (1) | WO2022229907A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024177036A1 (ja) * | 2023-02-20 | 2024-08-29 | 大鵬薬品工業株式会社 | Ftd・tpi配合剤、pd-1経路アンタゴニスト、及びvegf経路アンタゴニストの併用 |
| WO2026074499A1 (en) * | 2024-10-03 | 2026-04-09 | Geistlich Pharma Ag | Methods and compositions for inhibiting c-myc |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1160443B (de) * | 1961-11-30 | 1964-01-02 | Hoechst Ag | Verfahren zur Herstellung von Tetrahydro-oxathiazin-dioxyden |
| GB8617482D0 (en) | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
| PT2861573T (pt) | 2012-06-18 | 2017-11-14 | Geistlich Pharma Ag | Derivados de oxatiazina como agentes antibacterianos e anticancerígeno |
| KR102594322B1 (ko) * | 2014-12-19 | 2023-10-26 | 가이스틀리히 파마 아게 | 옥사티아진-유사 화합물의 제조방법 |
| US20220313702A1 (en) | 2019-05-22 | 2022-10-06 | Geistlich Pharma Ag | Oxathiazin compounds for inhibiting gapdh |
-
2022
- 2022-04-28 AU AU2022267897A patent/AU2022267897A1/en not_active Abandoned
- 2022-04-28 WO PCT/IB2022/053973 patent/WO2022229907A1/en not_active Ceased
- 2022-04-28 KR KR1020237035237A patent/KR20240004303A/ko active Pending
- 2022-04-28 CA CA3216783A patent/CA3216783A1/en active Pending
- 2022-04-28 JP JP2023565466A patent/JP2024515215A/ja active Pending
- 2022-04-28 EP EP22722576.0A patent/EP4330238A1/en active Pending
- 2022-04-28 US US18/556,480 patent/US12612375B2/en active Active
- 2022-04-28 CN CN202280031909.6A patent/CN117295720A/zh active Pending
- 2022-04-28 IL IL307990A patent/IL307990A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12612375B2 (en) | 2026-04-28 |
| JP2024515215A (ja) | 2024-04-05 |
| KR20240004303A (ko) | 2024-01-11 |
| US20240199563A1 (en) | 2024-06-20 |
| CN117295720A (zh) | 2023-12-26 |
| AU2022267897A1 (en) | 2023-11-02 |
| CA3216783A1 (en) | 2022-11-03 |
| EP4330238A1 (en) | 2024-03-06 |
| WO2022229907A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2508110C2 (ru) | КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek | |
| ZA200509515B (en) | Pharmaceutical composition containing histone deacetylase inhibitor | |
| RU2010117635A (ru) | Комбинированная химиотерапия | |
| US20220000835A1 (en) | Method for treating cancer with a combination of quercetin and a chemotherapy agent | |
| JP2003533485A5 (https=) | ||
| RS58608B1 (sr) | Kombinovana terapija sa antitumorskim antibiotikom | |
| NZ506187A (en) | Use of epothilones for the treatment of cancer | |
| JP2005509599A (ja) | 抗癌組み合わせ | |
| Spalding et al. | New and emerging radiosensitizers and radioprotectors | |
| WO2006065780A2 (en) | Combinations of therapeutic agents for treating cancer | |
| IL307990A (en) | Antimicrobial and anticancer agents | |
| KR20100126479A (ko) | 개선된 항종양 치료법들 | |
| Adjei | Current status of pyrazoloacridine as an anticancer agent | |
| MX2008014404A (es) | Tratamientos anticancer con combinacion de docetaxel y ecteinascidin. | |
| Belani | Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma | |
| JP2024515215A5 (https=) | ||
| US20200405752A1 (en) | Antitumor agent, antitumor effect enhancer, and antitumor kit | |
| US20030045562A1 (en) | Treatment of inflammatory, cancer, and thrombosis disorders | |
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| US20090281105A1 (en) | Radiotherapy enhancer | |
| ZA200200889B (en) | Combination therapy using pentafluorobenzenesulfonamides. | |
| Czito et al. | A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma | |
| Fracasso et al. | Phase I study of rubitecan and gemcitabine in patients with advanced malignancies | |
| RU2026108802A (ru) | Терапия рака, включающая соединение 3,5-дизамещенного бензолалкинила и ингибитор иммунных контрольных точек | |
| Cervantes et al. | State of the art treatment for gastric cancer: future directions |